Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health (NYSE: EVH) announced participation in several upcoming investor conferences. Chief Financial Officer John Johnson and Vice President of Investor Relations Seth Frank will represent the company. Details include:
- March 7, 2023: Cowen 43rd Annual Healthcare Conference in Boston at 10:30 a.m. ET.
- March 13, 2023: Annual Jefferies Value-Based Healthcare Summit in Miami Beach (no webcast).
- March 14, 2023: Barclays Global Healthcare Conference in Miami Beach at 3:35 p.m. ET.
Webcast recordings will be available on the investor relations section of Evolent's website. Evolent Health focuses on clinical and administrative solutions that improve health care affordability and accessibility.
Evolent Health (NYSE: EVH) reported Q4 and full-year 2022 financial results, showing significant growth. Q4 revenue reached $382.4 million, up 54.0% year-over-year, while full-year revenue totaled $1.35 billion, a 48.9% increase. Despite revenue growth, the company faced a net loss of $11.3 million for Q4, resulting in a net loss margin of (3.0)%. Total Lives on Platform expanded to 20.6 million. For 2023, Evolent secured new partnerships, including a significant sale expected to generate over $250 million in revenue for 2024. The company anticipates first-quarter revenue between $420 million and $440 million and full-year revenue of approximately $1.92 to $1.96 billion.
Evolent Health, Inc. (NYSE: EVH) has announced that it will release its fourth quarter 2022 financial results on February 22, 2023, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Shareholders and interested parties can listen to the call by dialing 855.940.9467 for domestic calls or 412.317.6034 for international access, referencing the Evolent Health call.
An audio playback will be available on the company's investor relations website for 90 days post-call. Evolent Health is known for delivering clinical and administrative solutions that enhance health care affordability and efficiency.
Evolent Health, Inc. (NYSE: EVH) announced participation in investor conferences featuring CEO Seth Blackley, CFO John Johnson, and VP Seth Frank. Key events include the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:30 a.m. ET and the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 4:30 p.m. ET. A live audio webcast will be available on Evolent's Investor Relations website. Evolent Health focuses on improving healthcare delivery through clinical and administrative solutions.
Evolent Health announced its agreement to acquire NIA, a specialty benefit management organization owned by Centene, for $650 million. The acquisition, set to close in mid-2023, is expected to add $85 million in adjusted EBITDA by 2024 and enhance Evolent’s value-based specialty care leadership. The deal diversifies Evolent's revenue base and increases cross-selling opportunities from $16 billion to $50 billion. The NIA acquisition will maintain Evolent's strong balance sheet and is projected to immediately improve cash flow and adjusted EBITDA margins.
Evolent Health, Inc. (EVH) reported a robust third quarter for 2022, generating $352.6 million in revenue, a 58.5% increase year-over-year. The company achieved a net income of $2.1 million with a margin of 0.6%, alongside an Adjusted EBITDA of $28.1 million and an 8.0% margin. Total lives on the platform reached 19.5 million. Evolent's new partnerships and acquisitions reflect sustained growth and innovation. For Q4 2022, revenue is projected between $361.0 million and $381.0 million, with full-year revenue guidance of $1.33 billion to $1.35 billion.
Evolent Health, Inc. (NYSE: EVH) has announced it will release its third quarter 2022 operating results on November 2, 2022, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Interested parties can join the call by dialing 855.940.9467 or 412.317.6034 for international access. An audio playback will be available on Evolent's investor relations website for 90 days post-call. Evolent Health focuses on delivering clinical and administrative solutions to improve healthcare efficiency and affordability.
Evolent Health (NYSE: EVH) announced participation in several investor conferences. CFO John Johnson and VP Investor Relations Seth Frank will present at the Wells Fargo Healthcare Conference on September 9, 2022, at 10:25 a.m. ET in Everett, MA. They will also conduct meetings at the Baird 2022 Global Healthcare Conference on September 13, 2022. Additionally, Frank will take part in the BofA Securities 2022 Healthcare Innovation Forum on September 29, 2022, with further details to be shared on the company's Investor Relations website. Webcast links will be available online.
Evolent Health (NYSE: EVH) announced Dan McCarthy's appointment as President, effective September 15, 2022. McCarthy, formerly CEO of New Century Health, will lead value-based specialty operations and oversee the integration of recent acquisitions into Evolent's platform. Frank J. Williams, co-founder and former CEO, will not seek re-election to the Board in June 2023. Both leaders emphasize a commitment to a seamless transition and continued growth.
Evolent Health, Inc. (NYSE: EVH) will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 4:30 p.m. ET. CEO Seth Blackley and VP of Investor Relations Seth Frank will lead investor meetings and present at the event held in Boston, Massachusetts.
A live audio webcast will be accessible on Evolent's Investor Relations website.
Evolent Health provides clinical solutions aimed at improving health care delivery.